preclinical development

Advertent Biotherapeutics, Inc. is a privately held biotechnology company advancing new therapies to help people maintain strength and mobility when muscle is damaged by genetic diseases, injury, or aging. Founded in 2019 as a spin-out from Michigan State University, it combines expertise in growth factor biology, muscle pathology, and drug development to build first-in-class biologics that protect muscle quality over the long term.

biologics discoverydrug developmentIND-enabling studiesstructure-guided protein engineering

Amygdala Neurosciences is a biopharmaceutical company headquartered in San Francisco, CA, founded in 2015. Its mission is to address the unmet need associated with alcohol use disorder (AUD) and other substance use disorders (SUD) by discovering, developing, and commercializing safe and effective pharmacotherapies to treat addiction. The company was formed based on technology targeting the enzyme aldehyde dehydrogenase type 2 (ALDH2), acquired from Gilead Sciences.

drug discoverypharmacotherapy development

ApoGlyx AB is a Swedish biopharmaceutical company founded in 2015 that develops first-in-class therapies based on aquaporin inhibitors. Its mission is to bring RG210179, a patented first-in-class Aquaporin-9 inhibitor for the treatment of acute pancreatitis, into a clinical development program. The company is located in Lund, within the Medicon Valley region.

drug discoverysmall molecule aquaporin-9 inhibitor development

BioVersys is an award-winning Swiss pharmaceutical company headquartered in Basel, Switzerland, focused on research and development of small molecules that work by novel modes of action and against novel targets to fight bacterial infections and antimicrobial resistance (AMR). Its pipeline includes BV100, Alpibectir, BV200, BV500 and discovery programs targeting serious hospital infections, MDR-TB, TB meningitis, S. aureus and NTM infections.

clinical developmentCMC strategy and operationsresearch and developmentsmall molecule drug discovery

Bonum Therapeutics uses a novel, antibody-based mechanism to create regulated and targeted, highly active, and less toxic medicines. Its therapeutics remain inactive until bound to their target, a reversible regulation mechanism. The company is developing antibody-controlled cytokine-based therapeutics designed to enhance the anti-tumor immune response, with two programs in preclinical development. Its pipeline is focused on cancer, with interest in autoimmune disease, metabolic disorders, and pain management.

antibody-based regulation mechanismprotein therapeutic engineering

BYOMass is a preclinical pharmaceutical company developing novel biologic and small molecule drugs to modulate specific members of the TGF-β superfamily, for the treatment of orphan and common diseases of high unmet medical need. It is pioneering a precision medicine approach targeting specific TGF-β superfamily members and pathways in oncology, inflammatory/immune, fibrotic, and metabolic diseases.

biologics developmentbiomarker stratificationdrug discoveryPK/PD modelingprecision medicinesmall molecule development

Celloram Inc. is a preclinical stage biopharmaceutical company founded in 2018 and located at University Circle, Cleveland, OH. It develops cell therapy and small molecule therapeutics targeting cancer, autoimmune, chronic inflammatory and metabolic disorders, with a pipeline of four therapeutics: Sopprimerex, Protexi, NOVS-100, and CLM-022.

cell therapy developmentsmall molecule drug development

CILA Therapeutics is a Boston-based biopharmaceutical company developing innovative therapies for patients with obstructive airway diseases. Its proprietary, gene-agnostic CIL-Key™ platform is designed to enable inhaled RNA therapeutics and vaccines for pulmonary diseases, and the company is committed to developing therapies to clear mucus obstruction.

inhaled RNA-LNP deliveryintracellular RNA delivery

ClotProtect Therapeutics Limited is a UK therapeutics spin-out from the University of Leeds developing a first-in-class small molecule anti-fibrinolytic (CP-101) to treat acute haemorrhage. The company is currently in preclinical development, aiming to identify a clinical drug candidate, and its approach promotes clot formation through a novel molecule and mechanism with superior efficacy and potency to the current standard of care (TXA).

drug discoverysmall-molecule therapeutics

Cognosci Inc. was founded in May 2000 to develop anti-inflammatory compounds for the treatment of neuroinflammatory diseases including Multiple Sclerosis, Alzheimer's Disease, and brain bleeding events. The company is discovering and developing therapeutic compounds based on the apoE protein, small patented synthetic peptides of ten to seventeen amino acids with anti-inflammatory and neuroprotective activity. Cognosci purchased rights to an APOE-based compound from Duke University and has engineered over 500 new compounds.

clinical trial developmentcompound engineeringdrug discoverylead optimization

Concarlo Therapeutics is a biotech company developing novel therapeutics to improve outcomes for cancer patients, using innovation in p27 biology. It is described as the first company to target CDK4/6-driven cell proliferation and CDK2-driven resistance. Its mission is to improve outcomes for patients with drug-resistant cancers by creating transformative therapies that control the p27 target.

computational biologydrug discoverymedicinal chemistrypeptide therapeutics

Corvidane is a privately held life sciences company developing novel therapeutic approaches for cardiometabolic disease, including atherosclerosis and metabolic dysfunction associated steatohepatitis (MASH). Its lead programme, CVMB-216, is a patented orally administered, multi-pathway therapeutic that activates a spectrum of clinically validated targets spanning lipid metabolism, inflammation and fibrosis. The company advances programmes through structured preclinical development toward regulated clinical pathways and pursues two indications for FDA app

clinical developmentdrug developmentprocess scale-uptherapeutic developmenttranslational research

Courage Therapeutics is a neuroendocrine company co-founded by Dr. Roger Cone that translates discoveries and novel chemistries into therapeutic candidates targeting the MC4R receptor. Its lead candidate, CTX-B, is a weekly injectable for the treatment of melanocortin-4 receptor haploinsufficiency (MC4R HI), a genetic obesity with no approved targeted therapeutic options.

drug discoveryIND-enabling programsmedicinal chemistry

DIMERx, Inc. is a clinical-stage biopharmaceutical company developing first-in-class, covalently linked dimer-based therapeutics to address major public-health challenges in pain management and the opioid crisis. Its pipeline includes DMX-101 (buprenorphine dimer, Phase 2), DMX-201 (arginine-agmatine dimer, IND-enabling) and DMX-105 (acetaminophen dimer, IND-enabling). Development is supported by competitive NIH awards, including an $18M mandate.

clinical developmentcovalent dimerization technology platformdrug discovery and developmentmedicinal chemistryregulatory strategy

DNA Nanobots, Inc. is a preclinical-stage platform technology company founded in 2021 in Columbus, Ohio, as a spin-out from The Ohio State University. It develops Genobots, non-viral delivery systems in which gene-bearing DNA is folded into a defined nanoscale structure carrying targeting and trafficking elements, building on over a decade of DNA-origami research. The architecture is being evaluated across genetic diseases including Duchenne muscular dystrophy; no program has been designated a lead and there are no approved products.

DNA origaminon-viral gene deliveryself-assembly

Drug Discovery Alliances provides a pharmaceutical R&D platform backed by an integrated team of CMC consultants and a global network of preferred suppliers, driving programs from discovery phase to commercialization. Founded in 2001 by Deborah Minor, Ph.D., the company supports biotech and pharmaceutical companies with drug discovery, drug development, CMC consulting, and regulatory support.

analytical method developmentantibody manufacturingAPI manufacturingcatalysis screeningCMC consultingcrystallizationformulation developmentGMP auditingGMP manufacturingIND application preparationmedicinal chemistryprocess researchregulatory supportsolid form screening

Emmaus Life Sciences, Inc. is a biopharmaceutical company engaged in the discovery, development and commercialization of innovative treatments and therapies primarily for rare and orphan diseases such as sickle cell disease, and is extending efforts to conditions affecting larger populations such as diverticulosis.

clinical developmentdiscovery, development and commercialization of treatments and therapies

Eradivir is a clinical-stage biotechnology company founded in March 2020 by Dr. Philip S. Low and Martin Low, based in West Lafayette, Indiana. It develops small molecules using its Bispecific Antigenic immuno-Therapy (BAiT) technology that target diseased cells and viruses, flagging them for clearance by the immune system. The company is developing therapies for influenza, RSV, and other serious diseases, including EV25 for influenza.

clinical developmentmedicinal chemistrysmall molecule drug discoveryvirology research

EVOQ Therapeutics develops innovative immunotherapies to restore immune tolerance and treat autoimmune diseases. Its proprietary NanoDisc technology delivers disease-specific antigens directly to dendritic cells in the lymph nodes, liver and spleen following subcutaneous administration, targeting the root cause of autoimmune disease. The approach has been proven in preclinical models for diseases like Type 1 Diabetes, Multiple Sclerosis, and Lupus, and EVOQ has eight programs moving toward the clinical stage through independent and partnered development.

immunotherapy developmentNanoDisc technologysubcutaneous administration

EydisBio is a small biotech startup based in Durham, NC focused on the development of highly selective and potent novel small molecule kinase inhibitors. Its current TAK1 program is described as the first to develop a highly selective, orally bioavailable inhibitor of TAK1 for the treatment of inflammatory-mediated diseases such as RA, systemic sclerosis, chronic pain, viral-induced ARDS, and SLE. The company uses its Universal Purinome Capture Platform (UPCP) chemoproteomics platform to identify protein kinases of interest.

chemoproteomics (Universal Purinome Capture Platform)purine-based small molecule compound developmentsmall molecule discovery and development

Faron Pharmaceuticals Ltd (AIM: FARN, First North: FARON) is a global, clinical-stage biopharmaceutical company focused on creating innovative cancer treatments that leverage the patient's own immune system. Its lead asset bexmarilimab is a first-in-class anti-Clever-1 antibody being investigated in Phase I/II clinical trials for hematological cancers and solid tumors.

clinical trialsdrug developmentimmunotherapy research

Fedora Pharmaceuticals Inc. is a Canadian clinical-stage biotechnology company based in Edmonton, Alberta, founded in 2011. It discovers and develops novel antibacterial therapies to combat antimicrobial resistance (AMR). Its pipeline includes nacubactam, a β-lactamase inhibitor/enhancer, and FPI-2119, a first-in-class non-β-lactam penicillin-binding protein inhibitor. The company's team also discovered tazobactam.

antibiotic discoverydrug developmentlicensingmedicinal chemistry

Feldan Therapeutics is a clinical-stage biotech company specializing in the development of treatments based on the intracellular delivery of therapeutics. It has developed the Feldan Shuttle®, a proprietary peptide-based technology enabling safe, rapid, and efficient delivery of antisense oligonucleotides (ASO) to cells, giving access to intracellular targets otherwise beyond reach. The company is conducting a Phase 1 clinical trial of FLD-103 for basal cell carcinoma and advancing FLD-201, an inhaled therapy for mucus-driven respiratory diseases, in pre

clinical developmentintracellular delivery of antisense oligonucleotides (ASO)peptide-based delivery technology

Functional Longevity Labs (FLL) is a Maryland-based early-stage pharmaceutical company founded in 2024 that develops therapeutics targeting the root biologic mechanisms of aging to maximize healthspan and delay age-associated disease. It operates under a CRADA with the National Institute on Aging at NIH and is developing FLL-001, a first-in-class YARS1 Chronomodulator for Alzheimer's disease.

biomarker-driven developmentdrug discoverygeroscience research